Trials Begin for Nasal Spray to Reduce COVID-19, Flu Infections

University of Maryland School of Medicine studying new approach to respiratory illness prevention

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

The University of Maryland School of Medicine is launching clinical trials on an experimental nasal spray aimed at boosting the immune system to reduce the likelihood of severe cold and flu illness. The spray is designed to be taken weekly during cold and flu season and is not a vaccine.

Why it matters

With the ongoing impacts of COVID-19 and the annual burden of influenza, new preventative measures that could reduce the severity of respiratory infections would be a significant public health advancement. This nasal spray approach represents a novel strategy compared to traditional vaccines.

The details

The clinical trials will determine whether the experimental nasal spray is effective at reducing the severity of cold and flu symptoms. Unlike a vaccine, the spray is designed to be taken weekly during the cold and flu season to bolster the body's natural immune defenses.

  • Clinical trials on the nasal spray are about to begin.

The players

University of Maryland School of Medicine

The academic medical center leading the research and clinical trials on the new nasal spray approach.

Got photos? Submit your photos here. ›

The takeaway

If proven effective, this nasal spray could provide an important new tool in the fight against seasonal respiratory illnesses like COVID-19 and the flu, potentially reducing the burden on healthcare systems and improving public health outcomes.